Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Accured Expenses (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Change in Accured Expenses data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 253.72% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $2.3 million, up 395.7%, while the annual FY2024 figure was -$671000.0, 193.72% down from the prior year.
  • Change in Accured Expenses reached $1.5 million in Q3 2025 per SNTI's latest filing, up from -$48000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.1 million in Q4 2021 and bottomed at -$2.9 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $290716.3, with a median of $33412.0 recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 68753.86% in 2022, down 137551.36% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $3.1 million in 2021, then tumbled by 81.58% to $567000.0 in 2022, then surged by 237.04% to $1.9 million in 2023, then grew by 6.28% to $2.0 million in 2024, then decreased by 27.38% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.5 million in Q3 2025, -$48000.0 in Q2 2025, and -$1.1 million in Q1 2025.